Drug repurposing of anti-infective clinical drugs: Discovery of two potential anti-cytokine storm agents.
Biomed Pharmacother
; 131: 110643, 2020 Nov.
Article
in English
| MEDLINE | ID: covidwho-726408
ABSTRACT
Coronavirus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2) has been widely spread in the world with a high mortality. Cytokine storm syndrome (CSS) and acute lung injury caused by SARS-CoV-2 infection severely threaten the patients. With the purpose to find effective and low-toxic drugs to mitigate CSS, entecavir and imipenem were identified to reduce TNF-α using a LPS-induced macrophage model from the anti-infective drug library. Entecavir and imipenem efficiently suppressed the release of inflammatory cytokines by partly intervention of NF-κB activity. The acute lung injury was also alleviated and the survival time was prolonged in mice. In addition, entecavir and imipenem inhibited the release of TNF-α and IL-10 in human peripheral blood mononuclear cells (hPBMCs). Collectively, we proposed that entecavir and imipenem might be candidates for the treatment of CSS.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Imipenem
/
Coronavirus Infections
/
Cytokine Release Syndrome
/
Guanine
Type of study:
Prognostic study
Topics:
Long Covid
Limits:
Animals
/
Humans
/
Male
Language:
English
Journal:
Biomed Pharmacother
Year:
2020
Document Type:
Article
Affiliation country:
J.biopha.2020.110643
Similar
MEDLINE
...
LILACS
LIS